Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
Multiple myeloma (MM) is an incurable plasma cell malignancy with a heterogeneous genetic background. Each MM subtype may have its own therapeutic vulnerabilities, and tailored therapy could improve outcomes. However, the cumulative frequency of druggable targets across patients is very low, which h...
主要な著者: | , , , |
---|---|
フォーマット: | 論文 |
言語: | English |
出版事項: |
Frontiers Media S.A.
2022-07-01
|
シリーズ: | Frontiers in Oncology |
主題: | |
オンライン・アクセス: | https://www.frontiersin.org/articles/10.3389/fonc.2022.961421/full |